Related Experiment Video

Updated: Jul 8, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.3K

FLT3 targeting in the modern era: from clonal selection to combination therapies

Vanessa E Kennedy1, Catherine C Smith2,3

  • 1Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, 505 Parnassus Ave, Box 1270, San Francisco, CA, 94143, USA.

International Journal of Hematology
|December 19, 2023
PubMed

Insights

Fms-like tyrosine kinase 3 (FLT3) mutations are common in acute myeloid leukemia (AML). FLT3 inhibitors are now key treatments for AML, improving outcomes across all disease phases.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Fms-like tyrosine kinase 3 (FLT3) is frequently mutated in acute myeloid leukemia (AML).
  • FLT3 mutations are a critical driver in AML pathogenesis.
  • Targeting FLT3 has become a cornerstone of modern AML therapy.

Purpose of the Study:

  • To review the current understanding of FLT3 biology in AML.
  • To discuss the clinical application of FLT3 inhibitors.
  • To explore resistance mechanisms and novel combination strategies.

Main Methods:

  • Literature review of FLT3 biology and FLT3 inhibitor clinical trials.
  • Analysis of current treatment guidelines and emerging research.
  • Synthesis of data on resistance patterns and combination therapies.

Main Results:

  • FLT3 inhibitors have significantly improved outcomes in AML.
  • FLT3 inhibitors are used in upfront, relapsed/refractory, and maintenance settings.
  • Understanding resistance mechanisms is crucial for optimizing therapy.

Conclusions:

  • FLT3 inhibitors represent a major advancement in AML treatment.
  • Further research into resistance and combination therapies is warranted.
  • Personalized treatment strategies targeting FLT3 are essential for AML management.
Keywords:
AMLAcute Myeloid LeukemiaClonal EvolutionFLT3FLT3 inhibitor

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

534

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529